This week, your Tisch MSRCNY researchers are at the Society for Neuroscience (SfN) in San Diego, CA presenting their research from our lab. Stay tuned for an article to learn more about their trip and the abstracts that they presented in the Fall Issue of the Healing MS Newsletter -- hitting your...
Over 1,000 people have already registered for the 21st Annual Tisch MS Research Center Patient Symposium. We have a great day planned. Seating is limited and registration is required. Reserve your spot today! https://tischmsrcnysymposium2018.eventbrite.com
In observance of Independence Day, the Tisch MS Research Center of New York will close today at 2:00pm and remain closed through the 4th. We wish our patients, friends and supporters a safe, happy and healthy 4th of July!
Your Tisch MS Researchers will be attending this year's 2018 AAN conference in Los Angeles California on April 21st-27th. Stay tuned for planned poster board presentations out of the Tisch MSRCNY lab! For more information on this year's conference, you can visit their website .
Due to the impending storm and weather conditions, the Tisch MS Research Center of New York will be closed on Wednesday, March 21, 2018. Please stay safe and warm!
written by Dr. Armistead Williams A new report from an annual meeting of hematologists showed positive results for using hematopoietic stem cell transplantation (AHSCT) to treat relapsing-remitting MS. The results reflect what we already know about AHSCT: that it is highly effective in relapsing-...
For Immediate Release RESEARCHERS SHOW STEM CELL THERAPY MAY REVERSE DISABILITY IN MULTIPLE SCLEROSIS New York, NY – February 6, 2018 – Researchers at Tisch MS Research Center of New York (Tisch MSRCNY) have shown a stem cell-based treatment may reverse disability in progressive multiple sclerosis...
This study, recently published in the journal JAMA Neurology, examined the use of Rituximab as a first-line MS treatment in Sweden. Rituximab is already extensively used in Sweden but this study showed the improved efficacy and safety of using Rituximab as a first MS treatment as compared to other...